Navigation Links
Peripheral Arterial Disease Costlier to Treat Than Heart Trouble
Date:1/23/2008

Prolonged recovery, potential for repeat treatments to blame, study finds

WEDNESDAY, Jan. 23 (HealthDay News) -- It costs about 5 percent more to treat people with peripheral arterial disease (PAD) than those with coronary artery disease (CAD), a U.S. study finds.

Both PAD (blocked abdomen and leg arteries) and CAD (blocked heart arteries) are treated with the same methods, including medication, surgery and endovascular techniques such as balloon angiography and stenting. The type of treatment depends on the location and severity of the disease.

Treatment tends to be more successful in CAD patients, which may explain why PAD costs more to treat, the study authors said.

"Patients with heart disease who get treated with a stent typically are doing just fine when seen six to 12 months later," principal investigator Dr. Michael R. Jaff, director of the Massachusetts General Hospital Vascular Center in Boston, said in a prepared statement. "Patients with PAD have to be seen frequently, and many of the treatments don't last as long, so it costs more to care for these patients."

This is because PAD-related blockages tend to be longer and more spread out, while CAD-related blockages are short and near the origin of the arteries.

In this study, Jaff and colleagues analyzed Medicare costs from 1999 to 2005 and found that, on average, the cost of initial treatment and one year of follow-up for PAD patients was $50,110, compared with $47,515 for CAD patients.

The researchers also noted that PAD is on the rise in the United States. About 8.2 percent of the Medicare patients included in the study had PAD in 1999, compared with about 9.5 percent in 2005. Most of the PAD patients were aged 65 or older.

Among the other findings from the study:

  • PAD patients with diabetes cost more to treat than those without diabetes, likely because those with diabetes have more extensive and severe PAD due to the effects of diabetes. About one-third of people with diabetes who are 50 or older have PAD, according to the American Diabetes Association.
  • Minimally invasive endovascular treatment tended to be more successful than surgery in PAD patients. This may be due to the prolonged recovery time for surgery and the potential for repeated treatments.

"These data suggest that future trials of PAD therapy should take into account the high cost of treating these patients, particularly those with diabetes mellitus," Jaff said. "When therapies work equally well, but there are cost advantages of one over the other, the less expensive therapy should be tried first."

The study was presented Monday at the annual International Symposium on Endovascular Therapy, in Hollywood, Fla.

About 8 million to 12 million Americans have PAD, which increases the risk of other cardiovascular disease, such as heart attack, stroke and aneurysm. PAD symptoms include limb pain, especially when walking, as well as numbness, skin discoloration and open sores that don't heal. However, many people with PAD have no symptoms.

More information

The Society for Vascular Surgery has more about peripheral arterial disease.



-- Robert Preidt



SOURCE: International Symposium on Endovascular Therapy, news release, Jan. 21, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
2. Riverside First to Offer New Treatment for Peripheral Arterial Disease
3. New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours
4. Spectranetics Receives Reimbursement Approval in Belgium for Lead Removal and Peripheral Atherectomy Products
5. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
6. American College of Physicians publishes "Peripheral Arterial Disease"
7. Peripheral Artery Disease Up Sharply Among U.S. Women
8. Asymptomatic peripheral artery disease prevalence is rising
9. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
10. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
11. Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Peripheral Arterial Disease Costlier to Treat Than Heart Trouble
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s ... June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... helping service members that have been wounded in battle and their families. Venture Construction ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
Breaking Medicine Technology: